Tuberculosis

Tuberculosis (TB) is still considered to be a global health problem and is caused by Mycobacterium tuberculosis (MTB) and Has affected humans for centuries. Our company is at the forefront of this battle, providing comprehensive vaccine and therapy development services.

Introduction to Tuberculosis

Tuberculosis (TB) is a communicable conditions brought on by the bacteria Mycobacterium tuberculosis (MTB) which mainly influences the lungs. TB can also affect other parts of the body. TB is spread through droplet nuclei resulting from the cough or sneeze of an affected person, which makes it very contagious. As per the World Health Organization's (WHO's) report, TB is still rated as one of the most dangerous infectious diseases, responsible for more than 1.2 million deaths around the world in 2018 alone, along with the high observed_ deaths from TB-HIV co-infection.

Fig.1 Typical tuberculous granuloma. (Cadena A. M., et al., 2017)

Vaccine Development for Tuberculosis

The prevention of tuberculosis majorly relies on vaccinations. The construction of the new tuberculosis vaccine consists of various parts whose end goal is to augment the immune response to MTB infection, disease development and curtail transmission. Although widely used, the bacillus Calmette-Guerin vaccine has inconsistent success in controlling the adult pulmonary variety of TB. Because of this inconsistency there has been a race for more effective and improved vaccines.

The quest for a more effective TB vaccine has led to the exploration of various platforms, including:

Table 1 Summary of tuberculosis (TB) vaccine candidates. (Li J., et al., 2020)

Therapeutics Development for Tuberculosis

Simultaneously with the work on the vaccine, new TB drugs and therapy methods must be developed. Progress in the management of multidrug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB) has also complicated the treatment's regimens, thereby requiring new drugs with new updated targets to be synthesized.

• First-Line Drugs: Isoniazid, rifampicin, ethambutol, and pyrazinamide continue to be the mainstay of tuberculosis therapeutics.
• Second-Line Drugs: For MDR-TB, fluoroquinolones, aminoglycoside injectables and newer agents such a bedaquiline and delamanid are used.
• Combination Therapies: The use of multiple drugs in combination is critical in combating drug resistant strains and providing better results.

The development of new TB drugs faces challenges such as lengthy and complex processes, the need for drugs with fewer side effects, and the emergence of resistance even to second-line drugs.

Our Services

As your trusted partner, our company is at the forefront of tuberculosis (TB) vaccine and therapy development, offering a comprehensive suite of services designed to accelerate the discovery and delivery of novel solutions to combat tuberculosis (TB).

Vaccine Development

• Live-attenuated Vaccine
• Inactivated Vaccine
• Toxoid Vaccine
• Viral Vector Vaccine
• Virus-like Particles Vaccine
• Protein Subunit Vaccine
• mRNA Vaccine
• DNA Vaccine

Therapeutic Development

• Small Molecule Drug
• Therapeutic mRNA
• Therapeutic Antibody
• Cell Therapy

Preclinical Research

• Drug Safety Evaluation
• In Vivo Pharmacokinetics Study
• In Vitro Pharmacokinetics Study
• Activity Testing
• Drug Resistance Evaluation

Disease Models

• C3HeB/FeJ Mouse Models: necrotic granulomas similar to those in humans
• Rabbit Models: for studying TB transmission, bone TB, and rarer forms of TB such as meningeal and cutaneous TB
• Non-Human Primate (NHP) Models

Our preclinical research services are designed to facilitate the thorough evaluation of tuberculosis (TB) vaccine and therapy candidates. We employ a variety of in vitro and in vivo models to assess the immunogenicity and therapeutic potential of new candidates. If you are interested in our services, please feel free to contact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.